Melanoma Diagnostics Therapeutics Market Size, Share, Trends & Forecast
The Melanoma Diagnostics Therapeutics Market is expanding as melanoma incidence, screening awareness, and access to advanced healthcare continue to increase. The market was valued at USD 5.2 billion in 2024 and is projected to reach USD 10.2 billion by 2035, growing at a 6.4% CAGR during 2026–2035.
Diagnostic innovation is being supported by artificial intelligence, machine learning, advanced imaging, and molecular testing. These technologies are helping improve melanoma detection and monitoring, while telemedicine is making dermatological consultations more accessible.
Biopsy remains a major diagnostic segment, valued at USD 1.5 billion in 2024 and projected to reach USD 3 billion by 2035. Imaging, blood tests, and genetic testing are also gaining importance, particularly as molecular diagnostics support more personalized treatment decisions.
The therapeutic landscape includes chemotherapy, immunotherapy, targeted therapy, and radiation therapy. Immunotherapy is particularly prominent, while targeted therapies are gaining attention because they can address specific genetic mutations associated with melanoma.
North America currently leads the market, while Asia-Pacific is expected to experience significant growth as awareness and healthcare access improve. Future opportunities are emerging through personalized medicine, non-invasive diagnostics, AI-enabled tools, and continued investment in innovative melanoma therapies.